

News release 2 July 2018

## PHYZAT ANNOUNCES R&D AGREEMENT WITH IPO PORTO

Porto, Portugal – Phyzat announced today an R&D agreement with Instituto Português de Oncologia do Porto Francisco Gentil EPE (IPO PORTO), the reference cancer institute in Northern Portugal, comprising several studies on the clinical validation of molecular targets in colorectal cancer (CRC) and its relevance in clinical options. The tests will be carried out at IPO Porto, over a period of 2 years, within the scope of the SIRNAC project.

Patrício Soares-da-Silva, CEO at Phyzat, commented: “IPO Porto has a long established expertise in the treatment of CRC and can provide large retrospective and prospective studies gathering fundamental information on the clinical relevance of the targets of our oncology innovative programs. This agreement allows Phyzat to benefit from that expertise in the validation of the clinical relevance of these specific targets and to integrate the findings into the design of our therapeutic strategy to treat medical conditions with highly unmet needs.”

The SIRNAC project is co-financed by



- END -

For enquiries, please contact:

Paulo Osswald | **Phyzat**  
e: paulo.osswald@phyzat.com  
T: +351 966 420 757

**Phyzat** is a biopharmaceutical company, incorporated in Porto to develop innovative RNA-based therapeutics with a discovery and clinical development program based on siRNA technologies. The SIRNAC project is a discovery and pre-clinical development project of proprietary RNAi based therapeutic solutions.

[www.phyzat.com](http://www.phyzat.com)